Even as two amyloid immunotherapies are in clinical use, scientists still have many questions about how these antibodies affect the brain. Neuropathology and biomarker data from treated patients are ...

More than two decades have passed since William Pardridge of the University of California, Los Angeles, used the analogy of a Trojan horse to describe molecular transport shuttles that can sneak ...

As amyloid immunotherapy enters clinical care in more countries, providers the world over are eager for more information on how well it works, and especially how safe it is. To collect such data in ...

Monoclonal antibodies continue to show their ability to rid the brain of amyloid plaques. Trouble is, those antibodies need to be injected on the regular to keep taking down their targets in the brain ...

This humanized IgG1 antibody inhibits an immune checkpoint protein called programmed death ligand, aka PD-L1, stimulating the immune system. Checkpoint inhibitors, including other antibodies, are ...

The center collects, processes, stores, and distributes samples, including longitudinal samples, from its research participants. Collections are taken from donors in their 40s to late 90s in a limited ...

reactive to aa 1-16 of Aβ and to APP; reacts to the abnormally processed isoforms, as well as precursor forms ...

This database is a repository of normal genetic variability, designed to be a tool for researchers who study neurodegenerative disease. It contains whole-exome sequencing results from nearly 500 ...

Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an Eli Lilly ...

The top-line results last September from Eisai’s Phase 3 trial of the anti-amyloid antibody lecanemab galvanized the field, but scientists said they needed to see the data before passing judgement.

Researchers led by Nicholas Ashton at the University of Gothenburg, Sweden, recently reported that ALZpath Inc.’s plasma phospho-tau217 assay detected amyloid and tau positivity with 92 to 97 percent ...

A top researcher’s fall from grace sends shock waves through the scientific community. Such is the case with neuropathologist Eliezer Masliah, who stands accused of image falsification spanning 26 ...